2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products

Code: 
2100

Most active institutional investors by number of deals

Pages

Most active individual investors by number of deals

Most active acquirers by number of deals

Investor Profile Country Deals
Pfizer Inc United States 6
Gilead Sciences Inc A biopharmaceutical company that discovers, develops and commercializes therapeutics. United States 3
Abbott Laboratories United States 2
Allscripts Healthcare Solutions Inc United States 1
Aquila Biopharmaceuticals Inc 1
Baxter International Inc United States 1
Biogen Idec Inc United States 1
Biovitrum AB Sweden 1
Corixa Corp United States 1
Cubist Pharmaceuticals Inc Cubist Pharmaceuticals is a bio-pharmaceutical company. 1
F Hoffmann-La Roche Ltd 1
Galapagos NV Belgium 1
GelTex Pharmaceuticals United States 1
Genzyme Corp United States 1
Johnson & Johnson Development Corp Inc United States 1
Pharmion Corp Initially, Pharmion concentrated its efforts on licensing products in the areas of hematology, oncology and supportive care. United States 1
Serologicals Corp United States 1

Acquisitions by industry of acquirer

Selected funding rounds

Date Company Profile Round Ccy Amount
23 Aug 2016 Vyome Biosciences Pvt Ltd Developer of medicines for treating skin diseases caused by resistant microbes. Series C USD 14,000,000
3 Nov 2015 FunkSac LLC Provider of customer services and compliant packaging solutions for the legal cannabis industry; both medical and recreational markets. N/A USD
3 Jul 2015 23andMe Inc DNA testing and genome sequencing firm. Series E USD 79,100,000
19 Jul 2014 23andMe Inc DNA testing and genome sequencing firm. Grant USD 1,400,000
15 May 2013 Tokai Pharmaceuticals Inc Developer of prostate cancer drugs Series E USD 35,000,000
10 May 2013 Trevena Inc Series C USD 60,000,000
19 Apr 2013 Allecra Therapeutics Developer of antibiotic treatments designed to combat multi drug-resistant gram-negative bacteria Series A EUR 15,000,000
4 Apr 2013 Aquinox Pharmaceuticals Inc Developer of small molecule therapeutics for the treatment of inflammatory disease Series C
28 Feb 2013 Kala Pharmaceuticals Inc Developer of products that penetrate the mucosal barrier to treat a variety of severe diseases Series A
2013 Arecor Ltd Developed a unique technology that is used in the formulation of biopharmaceuticals. N/A
21 Dec 2012 23andMe Inc DNA testing and genome sequencing firm. Series D USD 57,900,000
Oct 2012 New Haven Pharmaceuticals Inc Specialty pharmaceuticals company developing proprietary prescription pharmaceuticals. Series A
Jun 2012 Auxogyn Inc Series B
Jun 2012 Ceptaris Therapeutics Inc Specialty pharmaceuticals company. Series D
Jun 2012 Oxford Immunotec Ltd N/A
May 2012 AssureRx Health Personalized medicine company specializing in pharmacogenetics Series C
Apr 2012 BioRelix Inc Advanced fight against drug resistant microbes by attacking novel targets with novel drugs. N/A USD 269,000
Apr 2012 ALDEA Pharmaceuticals N/A
22 Mar 2012 BioRelix Inc Advanced fight against drug resistant microbes by attacking novel targets with novel drugs. N/A USD 2,560,000
15 Mar 2012 Kala Pharmaceuticals Inc Developer of products that penetrate the mucosal barrier to treat a variety of severe diseases Other venture

Pages

Selected acquisitions

Date Company Profile Country Ccy Amount
24 Oct 2011 Adolor Corp United States
Apr 2011 Calistoga Pharmaceuticals Inc Biopharmaceutical company dedicated to developing targeted therapies to improve the health of patients with cancer or inflammatory diseases. United States
14 Apr 1998 VacTex Inc
16 Aug 1999 SunPharm Corp Engaged in the development of small molecule pharmaceutical products United States
1 Feb 2007 BioRexis Pharmaceutical Corp United States
16 Jul 2003 RxCentric Inc Pharmaceutical marketing and detailing company via the internet. United States
11 Sep 2000 GelTex Pharmaceuticals United States
21 Jul 1999 Centocor Inc United States
16 Jun 2005 Vicuron Pharmaceuticals Inc United States
7 Sep 2004 Upstate Group Inc Develops and supplies research reagents and services to the pharmaceutical and life sciences research community. United States
12 Jul 1999 Perclose Inc United States
16 Oct 2000 Coulter Pharmaceutical Inc United States
24 Feb 2005 IDUN Pharmaceuticals Inc United States
4 Dec 2002 Triangle Pharmaceuticals Inc Anti-viral and oncology licensing company. United States
20 Jul 2011 Icagen Inc Biopharmaceutical company developing small molecule therapeutics that target ion channels for treatment of a variety of diseases. United States
3 Mar 2008 Serenex Inc Oncology-focused drug development company United States
3 May 2006 Conforma Therapeutics Corp Novel drugs company for the selective treatment of cancer. United States
15 Nov 2006 Cabrellis Pharmaceuticals Corp Development of important therapies for the treatment of cancer United States
1 Sep 2010 FoldRx Pharmaceuticals Inc United States
11 Sep 2009 Evalve Inc United States

Pages

Selected IPOs

Date Company Profile Country
Aug 2010 NuPathe Inc Developer of branded therapeutics for neurological and psychiatric disorders. United States
Xenogen Corp United States
Telios Pharmaceuticals Inc United States
VidaMed Inc United States

Selected companies

Company type: 
Developer of medicines for treating skin diseases caused by resistant microbes.
Company type: 
Provider of customer services and compliant packaging solutions for the legal cannabis industry; both medical and recreational markets.
Company type: 
Discoverer and developer of small molecule drugs for osteoarthritis/ inflammation and type II diabetes.
Company type: 
Drug discovery company committed to the development of breakthrough medicines for the treatment of cancer.
Company type: 
Advanced fight against drug resistant microbes by attacking novel targets with novel drugs.
Subscribe to RSS - 2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products